(SOON) Sonova H - SW
Sector: Healthcare | Industry: Medical Devices | Exchange: SW (Switzerland) | Market Cap: 11.917m CHF | Total Return: -19.4% in 12m
Avg Turnover: 31.9M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Sonova Holding AG is a Switzerland-based provider of comprehensive hearing care solutions, operating across four global regions. The company manages a vertically integrated business model that includes the design and manufacture of hearing aids, cochlear implants, and consumer-focused audio devices under brands such as Phonak, Advanced Bionics, and Sennheiser. Its distribution strategy combines wholesale operations with an extensive direct-to-consumer retail network of clinics and stores.
The hearing health sector is characterized by high barriers to entry due to stringent medical device regulations and the technical complexity of miniaturized electronics. Sonova competes in an oligopolistic market where growth is primarily driven by aging global demographics and the increasing integration of artificial intelligence into audiological hardware. For a deeper look at the fundamental metrics driving this sector, consider reviewing the latest data on ValueRay.
Founded in 1947, the company has evolved from a specialized instrument manufacturer into a diversified healthcare entity. It currently focuses on lifestyle-aligned segments, which bridge the gap between traditional medical hearing aids and high-end consumer audio technology through digital connectivity and speech-enhancement software.
- New product launches and AI integration drive market share gains
- Managed care expansion in US market pressures wholesale margins
- Audiological care network expansion increases vertical integration and recurring revenue
- Sennheiser consumer division integration improves lifestyle-aligned segment profitability
| Net Income: 542.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.37 > 1.0 |
| NWC/Revenue: 24.82% < 20% (prev 10.64%; Δ 14.19% < -1%) |
| CFO/TA 0.12 > 3% & CFO 684.1m > Net Income 542.3m |
| Net Debt (1.23b) to EBITDA (1.93b): 0.64 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 1.02% < -2% |
| Gross Margin: 72.95% > 18% (prev 72.04%; Δ 0.92% > 0.5%) |
| Asset Turnover: 62.42% > 50% (prev 65.25%; Δ -2.82% > 0%) |
| Interest Coverage Ratio: 58.23 > 6 (EBIT TTM 1.67b / Interest Expense TTM 28.7m) |
| A: 0.16 (Total Current Assets 2.08b - Total Current Liabilities 1.19b) / Total Assets 5.63b |
| B: 0.63 (Retained Earnings 3.52b / Total Assets 5.63b) |
| C: 0.29 (EBIT TTM 1.67b / Avg Total Assets 5.78b) |
| D: 0.87 (Book Value of Equity 2.61b / Total Liabilities 2.99b) |
| Altman-Z'' = 5.94 = AAA |
| DSRI: 1.05 (Receivables 665.1m/681.1m, Revenue 3.61b/3.87b) |
| GMI: 0.99 (GM 72.04% / 72.95%) |
| AQI: 0.92 (AQ_t 0.52 / AQ_t-1 0.57) |
| SGI: 0.93 (Revenue 3.61b / 3.87b) |
| TATA: -0.03 (NI 542.3m - CFO 684.1m) / TA 5.63b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of June 19, 2026, the stock is trading at CHF 196.40 with a total of 124,074 shares traded.
Over the past week, the price has changed by -2.66%,
over one month by +2.38%,
over three months by +4.46% and
over the past year by -19.43%.
Sonova H has no consensus analysts rating.
P/E Trailing = 22.2642
P/E Forward = 18.7617
P/S = 3.3047
P/B = 4.5589
P/EG = 1.2029
Revenue TTM = 3.61b CHF
EBIT TTM = 1.67b CHF
EBITDA TTM = 1.93b CHF
Long Term Debt = 1.35b CHF (from longTermDebt, last quarter)
Short Term Debt = 186.3m CHF (from shortTermDebt, last quarter)
Debt = 1.95b CHF (from shortLongTermDebtTotal, last quarter) + Leases 240.9m
Net Debt = 1.23b CHF (calculated: Debt 1.95b - CCE 722.1m)
Enterprise Value = 13.1b CHF (11.9b + Debt 1.95b - CCE 722.1m)
Interest Coverage Ratio = 58.23 (Ebit TTM 1.67b / Interest Expense TTM 28.7m)
EV/FCF = 21.81x (Enterprise Value 13.1b / FCF TTM 602.7m)
FCF Yield = 4.58% (FCF TTM 602.7m / Enterprise Value 13.1b)
FCF Margin = 16.71% (FCF TTM 602.7m / Revenue TTM 3.61b)
Net Margin = 15.04% (Net Income TTM 542.3m / Revenue TTM 3.61b)
Gross Margin = 72.95% ((Revenue TTM 3.61b - Cost of Revenue TTM 975.3m) / Revenue TTM)
Gross Margin QoQ = 77.20% (prev 68.76%)
Tobins Q-Ratio = 2.34 (Enterprise Value 13.1b / Total Assets 5.63b)
Interest Expense / Debt = 1.47% (Interest Expense 28.7m / Debt 1.95b)
Taxrate = 14.91% (95.7m / 641.7m)
NOPAT = 1.42b (EBIT 1.67b * (1 - 14.91%))
Current Ratio = 1.75 (Total Current Assets 2.08b / Total Current Liabilities 1.19b)
Debt / Equity = 0.75 (Debt 1.95b / totalStockholderEquity, last quarter 2.61b)
Debt / EBITDA = 0.64 (Net Debt 1.23b / EBITDA 1.93b)
Debt / FCF = 2.04 (Net Debt 1.23b / FCF TTM 602.7m)
Total Stockholder Equity = 2.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.39% (Net Income 542.3m / Total Assets 5.63b)
RoE = 21.70% (Net Income TTM 542.3m / Total Stockholder Equity 2.50b)
RoCE = 43.39% (EBIT 1.67b / Capital Employed (Equity 2.50b + L.T.Debt 1.35b))
RoIC = 31.98% (NOPAT 1.42b / Invested Capital 4.45b)
WACC = 6.72% (E(11.9b)/V(13.9b) * Re(7.62%) + D(1.95b)/V(13.9b) * Rd(1.47%) * (1-Tc(0.15)))
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.43 | Cagr: -1.67%
[DCF] Terminal Value 74.26% ; FCFF base≈624.1m ; Y1≈583.8m ; Y5≈536.9m
[DCF] Fair Price = 122.1 (EV 8.48b - Net Debt 1.23b = Equity 7.25b / Shares 59.4m; r=8.35% [WACC [floored]]; 5y FCF grow -8.14% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 29.02 | Revenue CAGR: 0.95% | SUE: -0.14 | # QB: 0
EPS current Year (2027-03-31): EPS=10.56 | Chg30d=-1.01% | Revisions=-22% | GrowthEPS=-1.0% | GrowthRev=+6.2%
EPS next Year (2028-03-31): EPS=11.69 | Chg30d=-0.29% | Revisions=-18% | GrowthEPS=+10.7% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: -22%